Screening for Disease
On this page
Direct answer
Screening is the presumptive identification of unrecognised disease or defect by applying tests, examinations or other procedures that can be applied rapidly to apparently healthy people. It sorts the population into those who probably have the condition and those who probably do not, and every positive must be confirmed by diagnostic testing — screening is not diagnosis. Whether a disease merits screening follows the classic Wilson-Jungner criteria, and the science of the topic rests on sensitivity, specificity, predictive value and the biases that distort screened populations' outcomes.
What you must remember
- Wilson-Jungner criteria: an important disease with a recognisable latent or presymptomatic stage; early treatment offering a better outcome; a suitable test that is sensitive, specific, simple, cheap, acceptable and reliable; facilities for diagnosis and treatment; and screening as a continuing process.
- Types: mass screening of the whole population versus selective screening of high-risk groups; multiphasic screening applies a battery of tests together.
- Sensitivity detects true disease; a sensitive test with few false negatives is preferred for serious treatable disease — a negative result rules out.
- Specificity identifies those without disease; a specific test with few false positives is preferred when a positive label causes harm — a positive result rules in.
- Positive predictive value rises with disease prevalence, the justification for targeting high-risk groups.
- Biases: lead-time (survival appears longer only because diagnosis is earlier), length (slow-growing disease preferentially detected), overdiagnosis and volunteer bias.
- Indian examples: screening everyone aged 30 and above for hypertension, diabetes and common cancers under the national NCD programme; visual inspection with acetic acid; oral visual examination in tobacco users.
Common confusion
A screening test is mistaken for a diagnostic test — screening sorts the apparently healthy and needs confirmation, whereas diagnosis establishes disease in a patient. Within test performance, sensitivity and specificity are intrinsic to the test, but predictive values change with prevalence, a fact most one-liners exploit. Lead-time and length bias are commonly interchanged: lead time is the extra observed survival created by earlier diagnosis with no true gain, while length bias is the over-representation of indolent disease among screen-detected cases.
Exam-focused takeaway
Expect two-by-two table items computing sensitivity, specificity and predictive values, true-false statements on the Wilson-Jungner criteria, and questions on when screening is unjustified — rare, incurable or rapidly fatal disease without a latent stage. Bias vignettes are frequent: a screened cancer cohort surviving longer than unscreened controls is the classic lead-time stem.
Frequently asked questions
What is the difference between screening and case-finding?
Screening is offered proactively to an apparently healthy population; case-finding searches for disease in people already in contact with health services for another reason.
What does a highly sensitive test ensure?
It detects nearly all true cases with few false negatives, so a negative result rules the disease out — preferred for serious treatable conditions.
Why does a test show higher positive predictive value in hospitals than in the community?
Hospital populations have higher disease prevalence, and predictive value rises with prevalence; in low-prevalence settings even a specific test yields many false positives.
What is lead-time bias?
The illusion of prolonged survival because screening advances the time of diagnosis without delaying death.
Why is screening unsuitable for a disease without a latent period?
There is no presymptomatic stage during which detection could help, so early diagnosis offers no advantage — a key Wilson-Jungner criterion.
Name screening tests used in India's NCD programme.
Blood pressure and blood glucose for everyone aged 30 and above, oral visual examination, clinical breast examination and visual inspection with acetic acid for cervical cancer.